Providers also have concerns about being able to stock certain medications, which would have a negative impact on their ...

An expert discusses how health plans currently don’t utilize real-world evidence for decision-making due to lack of common standards and limited data at drug launch, but explains that AMCP is ...

An expert discusses how health plans evaluate high-cost NMIBC therapies by examining total cost of care, weighing risk versus reward for treatments like gene therapy that can cost over a million ...

Using heart rate variability as a potential biomarker for diagnostic support and early screening of schizophrenia and bipolar disorder could eventually lead to faster, less costly assessments outside ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

New research uncovers how cancer-induced nerve injury drives resistance to anti-PD-1 therapy, revealing potential strategies to enhance treatment efficacy.

Results show that GLP-1s may address rheumatoid arthritis (RA) symptoms, independent of established weight loss and cardiac benefits, by reducing the systemic, chronic inflammation associated with RA.

The NIH is funding a new study at Weill Cornell that aims to identify the regulatory roles of gene variants involved in Type ...